Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2018

View Archived Issues

Mir-425 expression levels guide treatment choice in acute myeloid leukemia

NIH grant to support advancement of heroin vaccine OPNT-005

Tesaro opens phase III study of platinum-based therapy with TSR-042 and niraparib in ovarian cancer

NeuroBo Pharmaceuticals set to advance two lead candidates

First proof-of-concept data on IB-MS in patients with inactive PrMS

Anaeropharma and Chugai sign collaborative research agreement in oncology

FDA approves Dupixent as add-on maintenance therapy for asthma

MacroGenics studies MGD-014 in patients with HIV infection on suppressive ART

Temple University patents serotonin 5-HT7 receptor ligands

New phase I trial investigates TRPH-222 in relapsed or refractory B-cell lymphoma

New phase II trial explores use of AC-203 for inherited epidermolysis bullosa

Matrix metalloproteinase inhibitor from Iproteos may hinder epileptogenesis

Arbutus Biopharma divulges new compounds for HBV infection

Merck Sharp & Dohme enrolling patients in phase I study of MK-8583 for HIV-1

Roche presents bacterial DNA gyrase and/or topoisomerase IV inhibitors

Takeda Pharmaceutical and Scohia Pharma patent NFE2-related factor 2 activators

Celgene starts phase III study of bb-2121 in relapsed and refractory multiple myeloma

Biohaven begins phase I study with intranasal third-generation CGRP receptor antagonist for migraine

Merck & Co. discloses new IDO1 inhibitors

Researchers discover possible gene causative of melorheostosis

TAT therapy with [225Ac]RPS-074 effective in prostate cancer model

ESMO 2018: Putting all your eggs in one basket the best way towards sarcoma progress

Researchers find TAF1 to be highly involved in neurodevelopment

The SLCO1B locus is downregulated in alcohol-associated chronic pancreatitis

First clinical data presented at ESMO for the GITR agonist MEDI-1873

LPS-induced inflammation affects uptake of PD-L1 tracer in vivo

AF-3581 demonstrates efficacy in animal models of mood disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....